Carphology
A phase 3 trial of rituximab vs ocrelizumab in newly diagnosed relapsing-remitting MS gave a remarkably diplomatic result.Rituximab was non-inferior to ocrelizumab in suppressing MRI disease activity between 6 and 24 months.Relapse, disability and cognitive outcomes were similar, although analyses were underpowered to exclude clinically important differences.The separation came with infection rates: 82% with rituximab vs 69% with ocrelizumab.Most were mild, but with no long-term safety data.However, rituximab's lower acquisition cost looks different when including recurrent infections.Patients might end up paying the difference in coughs and antibiotics.
Authors
- A Fo Ben
Publication Details
- Journal
- Practical Neurology
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1136/pn-2026-005503
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00